LLY

726.05

-4.28%↓

UNH

509.38

-0.31%↓

JNJ

146.98

-0.66%↓

NVO

78.73

-5.4%↓

MRK

98.01

-2.68%↓

LLY

726.05

-4.28%↓

UNH

509.38

-0.31%↓

JNJ

146.98

-0.66%↓

NVO

78.73

-5.4%↓

MRK

98.01

-2.68%↓

LLY

726.05

-4.28%↓

UNH

509.38

-0.31%↓

JNJ

146.98

-0.66%↓

NVO

78.73

-5.4%↓

MRK

98.01

-2.68%↓

LLY

726.05

-4.28%↓

UNH

509.38

-0.31%↓

JNJ

146.98

-0.66%↓

NVO

78.73

-5.4%↓

MRK

98.01

-2.68%↓

LLY

726.05

-4.28%↓

UNH

509.38

-0.31%↓

JNJ

146.98

-0.66%↓

NVO

78.73

-5.4%↓

MRK

98.01

-2.68%↓

Search

AbbVie Inc

Cerrado

Sector Salud

171.37 -1.34

Resumen

Variación precio

24h

Actual

Mínimo

171.26

Máximo

173.86

Métricas clave

By Trading Economics

Ingresos

191M

1.6B

Ventas

14B

P/B

Media del Sector

61.995

59.526

BPA

3

Rentabilidad por dividendo

3.14

Margen de beneficio

10.795

EBITDA

1B

6B

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+18.03 upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

3.14%

2.33%

Próximas Ganancias

31 ene 2025

Fecha Próximo Dividendo

14 feb 2025

Próxima Fecha de Ex Dividendo

11 abr 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-15B

302B

Apertura anterior

172.71

Cierre anterior

171.37

Noticias sobre sentimiento de mercado

By Acuity

31%

69%

84 / 392 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

AbbVie Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

13 dic 2024, 14:54 UTC

Adquisiciones, fusiones, absorciones

AbbVie Buying Nimble Therapeutics for $200 Million to Boost Immunology Pipeline

11 nov 2024, 15:43 UTC

Principales Movimientos del Mercado

AbbVie Shares Slide, Bristol Myers Shares Rise After Schizophrenia Study Setback -- Update

11 nov 2024, 15:25 UTC

Principales Movimientos del Mercado

AbbVie Shares Slide, Bristol Myers Shares Rise After Schizophrenia Study Setback

30 oct 2024, 12:31 UTC

Ganancias

AbbVie Lifts Outlook After Arthritis Drugs Boost 3Q Sales

10 ene 2025, 13:36 UTC

Adquisiciones, fusiones, absorciones

AbbVie Estimates Non-Cash After-Tax Intangible Asset-Impairment Charge of About $3.5B >ABBV

10 ene 2025, 13:35 UTC

Adquisiciones, fusiones, absorciones

AbbVie to Record Impairment Charge Related to the Emraclidine Intangible Asset From Acquisition of Cerevel Therapeutics

1 ene 2025, 08:30 UTC

Principales Noticias

Drug-Trial Results Could Shake Up Pharma Stocks in 2025. Watch Eli Lilly, Pfizer, and More. -- Barrons.com

13 dic 2024, 14:39 UTC

Adquisiciones, fusiones, absorciones

AbbVie Buying Nimble Therapeutics for $200M to Boost Immunology Pipeline

13 dic 2024, 14:16 UTC

Adquisiciones, fusiones, absorciones

AbbVie: Nimble Shareholders Eligible for Potential Development Milestone Payment >ABBV

13 dic 2024, 14:15 UTC

Adquisiciones, fusiones, absorciones

AbbVie to Buy Nimble Therapeutics for $200 Million in Cash >ABBV

13 dic 2024, 14:15 UTC

Adquisiciones, fusiones, absorciones

AbbVie To Acquire Nimble Therapeutics, Further Strengthening Immunology Pipeline >ABBV

11 dic 2024, 14:15 UTC

Adquisiciones, fusiones, absorciones

AbbVie Completes Acquisition Of Aliada Therapeutics >ABBV

12 nov 2024, 12:00 UTC

Principales Noticias

What the NFL Draft Can Teach Investors About Big Pharma -- Heard on the Street -- WSJ

11 nov 2024, 15:47 UTC

Principales Noticias

AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps. -- Barrons.com

11 nov 2024, 15:23 UTC

Principales Noticias

AbbVie Stock Falls Sharply as Schizophrenia Therapy Shows No 'Significant' Improvement -- Barrons.com

11 nov 2024, 14:25 UTC

Principales Noticias

AbbVie Stock Falls Sharply as Schizophrenia Therapy Shows No 'Significant' Improvement -- Barrons.com

30 oct 2024, 13:39 UTC

Ganancias

AbbVie Stock Rises After Earnings Beat, Dividend Hike -- Barrons.com

30 oct 2024, 12:55 UTC

Charlas de Mercado
Ganancias

AbbVie Maintains Dividend Royalty With Increase -- Market Talk

30 oct 2024, 12:49 UTC

Ganancias

AbbVie Has A New Cash Cow As Humira Bows To Skyrizi In Third-Quarter Beat -- IBD

30 oct 2024, 12:34 UTC

Ganancias

AbbVie Stock Rises After Earnings Beat, Dividend Hike -- Barrons.com

30 oct 2024, 11:42 UTC

Ganancias

AbbVie: Dividend Payable Feb 14 to Hldrs of Record as of Jan 15 >ABBV

30 oct 2024, 11:41 UTC

Ganancias

AbbVie Raises Dividend to $1.64 Vs. $1.55 >ABBV

30 oct 2024, 11:40 UTC

Ganancias

AbbVie: Guidance Includes Unfavorable Impact of $0.64 Per Shr Related to Acquired IPR&D and Milestones Expense Incurred Yr-to-date Through 3Q >ABBV

30 oct 2024, 11:39 UTC

Ganancias

AbbVie Had Seen FY24 Adjusted EPS of $10.67 - $10.87 >ABBV

30 oct 2024, 11:38 UTC

Ganancias

AbbVie 3Q Global Skyrizi Rev $3.21B >ABBV

30 oct 2024, 11:38 UTC

Ganancias

AbbVie 3Q EPS 88c >ABBV

30 oct 2024, 11:38 UTC

Ganancias

AbbVie 3Q Global Net Rev From Oncology Portfolio $1.69B >ABBV

30 oct 2024, 11:38 UTC

Ganancias

AbbVie 3Q Adj EPS $3.00 >ABBV

30 oct 2024, 11:38 UTC

Ganancias

AbbVie 3Q Net $1.56B >ABBV

30 oct 2024, 11:38 UTC

Ganancias

AbbVie 3Q Global IMBRUVICA Rev $828M >ABBV

Comparación entre iguales

Cambio de precio

AbbVie Inc Esperado

Precio Objetivo

By TipRanks

18.03% repunte

Estimación a 12 meses

Media 202.5 USD  18.03%

Máximo 240 USD

Mínimo 165 USD

De acuerdo con 19 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para AbbVie Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

19 ratings

13

Comprar

6

Mantener

0

Vender

Puntuación técnica

By Trading Central

170.52 / 174.34Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Very Strong Bearish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

84 / 392 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de AbbVie Inc

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. AbbVie offers its products in various therapeutic categories, including Immunology products, which include Humira, Skyrizi and Rinvoq; Oncology products consists of Imbruvica and Venclexta; Aesthetics products include Botox Cosmetic, Juvederm Collection and other aesthetics; Neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; Eye care products consists of Lumigan, Alphagan and Restasis ; Women's health products incudes Lo Loestrin, Orilissa and other women's health; and Other key products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. The Company's products are sold worldwide directly to wholesalers, distributors, government agencies, health care facilities and independent retailers from AbbVie-owned distribution centers and public warehouses.